THERAPEUTIC FOCUS

NeurAegis has identified several calpain-2 inhibitors that provide an unprecedented level of neuroprotection in several preclinical models of neurodegenerative disorders. Our initial focus is on developing a first-in-class treatment for concussion, followed by additional earlier stage programs for acute glaucoma, epilepsy and mild cognitive impairment.

Traumatic brain injury is the leading cause of death and disability for children and young adults in the U.S. Approximately 1.7 million people sustain a TBI each year in the U.S. alone, with 75% of these classified as a concussion. Currently there are no FDA-approved therapies for TBI or concussion.

Brain Impacting the Inside of the Skull

Concussions are especially dangerous when compounded by multiple occurrences. For example, research has connected the deaths of several professional athletes that have been found to have chronic traumatic encephalopathy (CTE), a disease that causes degeneration of the brain.